2seventy bio’s Post

What are the current emerging trends in allogeneic cell therapy? Dive into our latest update to learn more about investor interest, technological advancements and the commercial drivers that are transforming the allogeneic cell therapy landscape: https://lnkd.in/eTgRNyWD #SyneosHealth ft. Samvar Shah, Harry Bickerstaffe, Gursharan Batra

Allogeneic cell therapies are on the rise! Interest in allogeneic cell therapies has been increasing steadily over recent years from our analysis, accounting for ~54% of cell therapy deal volume in the most recent year (~24% deal value). Commercial drivers are fueling investor interest with the potential of allogeneic approaches to revolutionalise patient care options in a greatly expanded population. Key technological barriers, primarily safety concerns in allorejection, graft versus host disease, and neurotoxicity are seeing a surge in novel technologies in clinical development that aim to overcome these hurdles. Read more in our short cell therapy update: https://lnkd.in/eTgRNyWD ft. Samvar Shah Gursharan Batra

Are you developing allogeneic cell therapies? How do you guarantee their compliant aseptic manufacturing?   To get the answers to those questions, you should attend Michela Castellani-Kleinschroth and Koji Ushioda's speech tomorrow at #ATE24     Phacilitate SKAN #AT #AdvancedTherapiesEurope #CellTherapy #AllogeneicTherapy

We’re 🤯 by the latest clinical trial research from Oncologie | UNIL-CHUV! Read our blog to see how they used #singlecell technologies to characterize the tumor-immune features that could be the key to successful adoptive cell therapy in metastatic #melanoma.

Scotty Chung-Siu, MPH, a managing analyst at GlobalData , revealed that the #APAC region leads with 1,023 single-country trials, significantly surpassing North America’s 476 trials. “The APAC region’s growing dominance holds potential to revolutionize adoptive cell therapy advancements,” said Chung-Siu. 👉 Learn more about APAC’s role in adoptive cell therapy advancements: https://bit.ly/3z9vRIL #AdoptiveCellTherapy #ClinicalTrials #CAR_T #Immunotherapy #BiotechInnovation #HealthcareAdvancements #ClinicalResearch #OutsourcingInClinicalTrials

Now that I’ve spent two months getting up to speed on all things Nomic Bio and #nELISA they are finally letting me out in public to speak with customers 😂 In all seriousness, this onboarding has been truly inspiring and solidified my initial hunch that this was a one-of-a-kind place with a legitimate paradigm-shifting technology. The opportunity to introduce researchers to our novel #proteomics solution at events like the #IOSummit here in Philadelphia is extremely motivating. In this industry, it isn’t often that you’re in a postition to solve several long-standing technical challenges while also lowering cost and increasing throughput! And while this is just the beginning, it’s becoming increasingly clear that access to a high-plex, #quantitative #immunoassay panel that enables turnkey flexibility while significantly reducing end-to-end cost is already redefining how, and more importantly how often, proteomics is applied from #drugdiscovery screening campaigns to translational #biomarker studies. I’m looking forward to sharing our advancements with a growing audience of scientists over the coming months and can’t wait to see how we together accelerate and ultimately enable the promise of proteomics.

⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART

What are the current emerging trends in allogeneic cell therapy? Dive into our latest update to learn more about investor interest, technological advancements and the commercial drivers that are transforming the allogeneic cell therapy landscape: https://ow.ly/ba7s30sFboq #SyneosHealth ft. Samvar Shah, Harry Bickerstaffe, Gursharan Batra

Join us on Tuesday, September 10 at 1 PM ET for a webinar where we’ll be discussing the advantages of negative selection for cell isolation. Learn more about the benefits of using untouched cells in cell therapy and hear from our expert panel on why Akadeum is leading the charge toward this important approach. https://hubs.li/Q02MdSRL0 #thepositivesofnegativeselection #bettertcells #cellisolation #negativeselectionatscale

🔍 Join our upcoming webinar to explore the latest advancements in CAR-T cell signaling and activation. Gain insights from leading experts on innovative non-viral editing 🧬 and analytical platforms that are revolutionizing the efficiency of CAR-T cell therapy. 🌟